Comparative Pharmacology
Head-to-head clinical analysis: KETOCONAZOLE versus TERAZOL 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOCONAZOLE versus TERAZOL 3.
KETOCONAZOLE vs TERAZOL 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450 14α-demethylase, impairing ergosterol synthesis and disrupting fungal cell membrane integrity.
Terconazole is an azole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and leads to fungal cell death.
200-400 mg orally once daily for superficial fungal infections; 400 mg orally once daily for systemic mycoses. Duration varies by indication.
One applicatorful (approximately 5 g of 0.8% terconazole vaginal cream) intravaginally once daily at bedtime for 3 consecutive days.
None Documented
None Documented
Clinical Note
moderateKetoconazole + Tranilast
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Tranilast."
Clinical Note
moderateKetoconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Tolfenamic acid."
Clinical Note
moderateKetoconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Nimesulide."
Clinical Note
moderateBiphasic elimination: initial half-life 2-4 hours, terminal half-life 6-10 hours in adults. In severe hepatic impairment, half-life may be prolonged up to 12-20 hours.
The terminal elimination half-life after intravaginal application is approximately 4-6 hours, reflecting local retention and slow systemic absorption of the small absorbed fraction.
Primarily metabolized in the liver; about 70% of the dose is excreted in feces via bile as metabolites, approximately 20-30% in urine (mostly as inactive metabolites), and less than 5% unchanged.
Following intravaginal administration, terconazole is minimally absorbed (<5%) into systemic circulation. Absorbed drug is primarily metabolized in the liver and excreted via feces (approximately 50-60% as metabolites) and urine (approximately 20-30% as metabolites). Unabsorbed drug is excreted in feces.
Category C
Category C
Azole Antifungal
Azole Antifungal
Ketoconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Risedronic acid."